Neuronetics (STIM)
(Real Time Quote from BATS)
$3.61 USD
+0.24 (7.12%)
Updated May 1, 2024 12:34 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
STIM 3.61 +0.24(7.12%)
Will STIM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for STIM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STIM
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
STIM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
The Cooper Companies (COO) Q1 Earnings and Revenues Top Estimates
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
Other News for STIM
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
Neuronetics advances NeuroStar TMS for adolescents
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Neuronetics announces publication of findings in Brain Stimulation